Tempest Therapeutics, Inc. — Director's Dealing 2020

Feb 4, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Millendo Therapeutics, Inc. (MLND)
CIK: 0001544227
Period of Report: 2020-01-31

Reporting Person: Arcudi III Louis J (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-31	Employee Stock Option (right to buy)	$7.94	A	71250	Acquired	2030-01-30	Common Stock (71250)	Direct

Footnotes

F1: Twenty-five percent (25%) of the shares subject to this option shall vest on January 7, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.